Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Research & Development: 2010-2025

Historic Research & Development for Catalyst Pharmaceuticals (CPRX) over the last 15 years, with Sep 2025 value amounting to $2.7 million.

  • Catalyst Pharmaceuticals' Research & Development fell 19.09% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.7 million, marking a year-over-year increase of 35.83%. This contributed to the annual value of $12.6 million for FY2024, which is 86.42% down from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Research & Development is $2.7 million, which was down 39.03% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Research & Development registered a high of $83.7 million during Q3 2023, and its lowest value of $2.0 million during Q4 2023.
  • In the last 3 years, Catalyst Pharmaceuticals' Research & Development had a median value of $3.6 million in 2023 and averaged $10.6 million.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Research & Development surged by 906.76% in 2023 and then crashed by 96.07% in 2024.
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' Research & Development stood at $5.0 million in 2021, then declined by 18.01% to $4.1 million in 2022, then slumped by 51.82% to $2.0 million in 2023, then surged by 92.60% to $3.8 million in 2024, then dropped by 19.09% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $4.4 million for Q2 2025, and $3.9 million during Q1 2025.